[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Anita Saraf\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100536071","phase-4-efficacy-of-sodium-glucose-transporter-inhibitor-sglt2i-in-adult-patients-with-congenital-heart-disease-100536071",false,"NCT06260059","Efficacy Of Sodium Glucose Transporter Inhibitor (SGLT2I) In Adult Patients With Congenital Heart Disease","Efficacy of Sodium Glucose Transporter Inhibitor (SGLT2i) in Adult Patients With Congenital Heart Disease","EmpaCHD","Inclusion Criteria:\n\n* Diagnoses of Congenital Heart Disease\n* Age 18+\n* ACHD level of structural complexity II or III\n* Recent (\\\u003C6 months) decrease in systemic Ejection Fraction (confirmed by cardiac Echocardiogram, Computed Tomography or cMRI) to EF \\\u003C 60%\n* Recent decrease in systemic ejection fraction confirmed by cardiac Echo, CT or MRI by \\> 5% in the last 6 months or less.\n* Must be able to complete neurocognitive assessments on a handheld computer.\n\nExclusion Criteria:\n\n* Diagnosed with Diabetes\n* Contraindication to Jardiance\u002FEntresto or any heart failure medication (per guideline-directed therapy, 2022).\n* Previous therapy with Jardiance at \\\u003C4 weeks\n* Glomerular Filtration Rate \\\u003C20\n* Pregnancy, breastfeeding, or planning to become pregnant in the coming year\n* History of liver disease - including non-alcoholic fatty liver disease (NAFLD) and cirrhosis\n* History of inborn error(s) of metabolism (including but is not exclusive of Glycogen storage disease type 1)\n* Glucose-galactose malabsorption, familial hyperinsulinism, maple syrup urine disease,\n* Gaucher disease,\n* Tay-Sachs disease,\n* Mucolipidosis IV,\n* Niemann-Pick disease,\n* Type A mitochondrial disease,\n* Metabolic disorders related to glucose metabolism","ALL","18 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The goal of the study is to investigate the feasibility and benefit of novel guideline-directed heart failure therapy drug Empagliflozin (Jardiance) for adult patients with congenital heart disease (ACHD).",[27,28],"Adult Congenital Heart Disease","Heart Failure",[30,31,32],"congenital heart disease","reduced exercise capacity","decreased cardiac function","RECRUITING","2025-10-02",{"date":36,"type":37},"2025-10-06","ACTUAL",{"date":39,"type":37},"2024-09-17",{"date":41,"type":21},"2027-06-01",{"name":43,"class":44},"Anita Saraf","OTHER",3,""]